inPractice® - Lopinavir/Ritonavir Monotherapy

Only 10% of virologically suppressed patients receiving lopinavir/ritonavir plus 2 NRTIs switched to lopinavir/ritonavir monotherapy experienced viral rebound if they had been virologically suppressed for ≥ 6 months before switching^{[Bierman 2009]}
- Patients experiencing virologic rebound were able to reattain virologic suppression with the reintroduction of NRTIs^{[Bierman 2009; Mathis 2011]}
Virologic rebound almost exclusively occurs in the absence of emergent PI resistance mutations^{[McKinnon 2011]}